cabergoline for prolactinoma high-dose
Selected indexed studies
- Treatment of Prolactinoma. (Medicina (Kaunas), 2022) [PMID:36013562]
- Giant Prolactinomas. (Neuroendocrinology, 2019) [PMID:30404098]
- Giant Prolactinoma Resistant to High-Dose Cabergoline in a Young Male Lost to Follow-Up. (Cureus, 2025) [PMID:41322860]
_Worker-drafted node — pending editorial review._
Connections
cabergoline for prolactinoma high-dose is a side effect of
Sources
- Treatment of Prolactinoma. (2022) pubmed
- Giant Prolactinomas. (2019) pubmed
- Giant Prolactinoma Resistant to High-Dose Cabergoline in a Young Male Lost to Follow-Up. (2025) pubmed
- Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. (2010) pubmed
- Update in prolactinomas. (2010) pubmed
- Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment. (2021) pubmed
- Prolactinomas in males: any differences? (2020) pubmed
- Aggressive prolactinomas: how to manage? (2020) pubmed
- Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. (2008) pubmed
- The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma. (2005) pubmed